"大腸がんに対する二週間に一度のトリフルリジン/ティピラシルとベバシズマブの患者内投与量エスカレーションに関する第2相試験 (E-BiTS試験) "への訂正: [ESMO Open. 第10巻 第9号 (2025年9月)
M Wakabayashi1, H Taniguchi2, A Makiyama3
1Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan; Department of Gastroenterology and Hepatology, Toho University Omori Medical Center, Tokyo, Japan.
ESMO open
|January 3, 2026
まとめ
No abstract available in PubMed .
関連する概念動画
Treatment Resistant Cancers
2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
84
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84


